About: Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published in The Lancet

Attributes	Values
rdf:type	Item
description	artículu científicu (ast) wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 2004 (uk) im Oktober 2004 veröffentlichter wissenschaftlicher Artikel (de) article publié dans la revue scientifique The Lancet (fr) scientific article published in The Lancet (en) ശാസ്ത്രപ്രബന്ധം (ml)
publication date	wds:Q57374095-B0770FFA-43A6-40B7-9454-62B0AE0D1DF3
publication date	2004-10-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57374095-A017038E-5488-4422-B99E-DF889EB741BF
language of work or name	English
cites work	wds:Q57374095-06B2D04C-BD38-408C-85EB-4CE32B44BACA wds:Q57374095-14E68909-BB1E-41A8-B7A7-8BE1FE6ED7C0 wds:Q57374095-16D146BB-8334-4769-9A70-4363F2CDDAFA wds:Q57374095-1DC7DAF7-E91D-4557-A537-C25469B367E5 wds:Q57374095-1F284838-ACED-422F-9246-F5194277036F wds:Q57374095-24078C25-C5EB-4356-A1C8-A0A2E1CE2D50 wds:Q57374095-268772E0-0B1E-48E7-9665-490F47A5878F wds:Q57374095-2E227B7E-20CA-4831-A677-70C8DF18A782 wds:Q57374095-31691D29-1DA8-49B0-8E45-53262466C532 wds:Q57374095-36BA0EB2-D4BC-48B8-9DFF-0FB5B3F6E6F5 wds:Q57374095-37CDE512-0E4E-4CE4-93C9-EDC9EDC642C5 wds:Q57374095-4CBE77AD-68CD-4FF3-A871-4C171E272221 wds:Q57374095-59A52317-5264-4001-A14D-E94E6BB56293 wds:Q57374095-5FEEC32B-C9F8-4739-9A36-CBD1797FBEC2 wds:Q57374095-64A9E2A1-A7E5-4025-BBB8-9AA36A68F81A wds:Q57374095-6B3CEE78-7E57-47D2-A437-F5B94CA294A2 wds:Q57374095-6B7895AF-38AC-42B7-9958-EC932DC38601 wds:Q57374095-780C7A88-A35C-47EF-85AE-6EF6D1A06765 wds:Q57374095-7DA33E8D-0654-4934-AC40-D4E67618A5CF wds:Q57374095-89F6F035-D6F1-4C7B-A355-B8B15E74AB7E wds:Q57374095-8CAE8A44-A9C8-4B90-A5FB-4DC620C34428 wds:Q57374095-952E7284-B319-42D5-90AD-C1CF6C9B3F9C wds:Q57374095-998F7BBF-68DB-4A88-9335-AF9A2F302DB8 wds:Q57374095-A0432610-CB6D-414D-ABE6-AE72B22B02F8 wds:Q57374095-A19AA819-2B76-46B6-94D2-7A96D3CBD268 wds:Q57374095-B60EFB4C-8649-4DBE-95E3-3335F13A3162 wds:Q57374095-B7161169-5F15-4788-91A7-FC90727B8EDD wds:Q57374095-BD08C286-7D09-424A-ABD4-A1A1AB59F57C wds:Q57374095-BD120A60-E011-4760-9126-81BC3E559750 wds:Q57374095-BD2D3DCC-08A8-4B3B-8A77-FF69E491AF72 wds:Q57374095-CFE1FBF5-A041-4AC2-88BC-A0A89EEC167B wds:Q57374095-D4E3031E-4A74-4185-A0B9-E22765E4AD88 wds:Q57374095-D9FF7068-0F64-40F0-8DD9-61CD41132069 wds:Q57374095-E1C1F19B-4169-4B27-A282-53B41221E82A wds:Q57374095-F2A76984-5225-405E-A0F0-E37080143E58 wds:Q57374095-F34E7E68-61CF-4DAD-A9E0-21D37C090584 wds:Q57374095-F5AFEFDD-C6EB-4724-8917-2D725D8C7F35 wds:Q57374095-FAE17ADC-76CB-43E1-8642-15DBE8BA9CDB wds:Q57374095-FDC1A3F3-086E-4CF1-8CC7-73A9F1F5FA19
cites work	Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis Axonal transection in the lesions of multiple sclerosis Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study Age-related changes in conventional, magnetization transfer, and diffusion-tensor MR imaging findings: study with whole-brain tissue histogram analysis. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. Multiple sclerosis Induction of sodium channel clustering by oligodendrocytes Normalized accurate measurement of longitudinal brain change. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis Synaptic efficacy enhanced by glial cells in vitro. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS. Detection of ventricular enlargement in patients at the earliest clinical stage of MS Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Eight-year follow-up study of brain atrophy in patients with MS. A neurologic rating scale (NRS) for use in multiple sclerosis Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images Inflammation in multiple sclerosis: the good, the bad, and the complex Optimizing the association between disability and biological markers in MS. Interferon beta in the treatment of multiple sclerosis: mechanisms of action Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a A comparison of the sensitivity of MRI after double- and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis☆ The effect of gadolinium-enhancing lesions on whole brain atrophy in relapsing-remitting MS
author name string	wds:Q57374095-067B1881-E991-4FBB-8890-B7F7E3468632 wds:Q57374095-ACCDE133-590A-4455-88B5-36C5DA207484 wds:Q57374095-B56AC461-F914-41BF-95FC-83546B31759E
author name string	Marco Rovaris Nicola De Stefano Matilde Inglese
rdfs:label	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial (en) Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial (nl)
skos:prefLabel	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial (en) Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial (nl)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software